Cellosaurus OCI-AML2 (CVCL_1619)

Cell line name OCI-AML2
Synonyms OCI AML2; OCI-AML-2; OCI/AML-2; OCIAML2; AML-2
Accession CVCL_1619
Resource Identification Initiative To cite this cell line use: OCI-AML2 (RRID:CVCL_1619)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
From: Ontario Cancer Institute (OCI); Toronto; Canada.
Doubling time: 30 hours (PubMed=25984343); ~30-50 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Disease Adult acute myeloid leukemia (NCIt: C9154)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_8391 (OU-AML-1); CVCL_8392 (OU-AML-2); CVCL_8393 (OU-AML-3); CVCL_8394 (OU-AML-4); CVCL_8395 (OU-AML-5); CVCL_8396 (OU-AML-6); CVCL_8397 (OU-AML-7); CVCL_8398 (OU-AML-8)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; PubMed=25877200

Markers:
AmelogeninX,Y
CSF1PO10,12
D13S31711,12
D16S53912,13
D18S5114
D21S1129
D3S135816
D5S81812
D7S82012
D8S117912,15
FGA19,24
Penta D12
Penta E12,14
TH016,9.3
TPOX11
vWA14,17
Publications

PubMed=2538684
Wang C., Curtis J.E., Minden M.D., McCulloch E.A.
Expression of a retinoic acid receptor gene in myeloid leukemia cells.
Leukemia 3:264-269(1989)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections BCRJ; 0383
DSMZ; ACC-99
ICLC; HTL01010
Cell line databases/resources CLDB; cl3760
CLDB; cl7059
CCLE; OCIAML2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cosmic-CLP; 910947
GDSC; 910947
LINCS_LDP; LCL-1065
Ontologies BTO; BTO:0004619
CLO; CLO_0008235
EFO; EFO_0006706
Biological sample resources BioSample; SAMN03473106
Chemistry resources ChEMBL-Cells; CHEMBL3308300
ChEMBL-Targets; CHEMBL2366220
Gene expression databases GEO; GSM482511
GEO; GSM887468
GEO; GSM888548
GEO; GSM1374780
GEO; GSM1446749
GEO; GSM1670295
Polymorphism and mutation databases Cosmic; 787466
Cosmic; 910947
Cosmic; 975288
Cosmic; 1012109
Cosmic; 1281344
Cosmic; 1319545
Cosmic; 1582386
Cosmic; 2131551
Cosmic; 2306231